Skip to main content
SpringerLink
Log in

Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C . Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 2007; 39: 253–254.

    Article  Google Scholar 

  2. Focosi D, Fazzi R, Montanaro D, Emdin M, Petrini M . Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res 2007; 74: 156–158.

    Article  CAS  Google Scholar 

  3. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 1380–1383.

    Article  CAS  Google Scholar 

  4. Altschuler EL, Kast RE . The atypical antipsychotic agents ziprasidone, risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses 2005; 65: 585–586.

    Article  CAS  Google Scholar 

  5. Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR et al. Positron emission tomographic analysis of central 5-hydroxytryptamine 2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996; 279: 939–947.

    CAS  PubMed  Google Scholar 

  6. Nyberg S, Dahl ML, Halldin C . A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995; 119: 345–348.

    Article  CAS  Google Scholar 

  7. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J . Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134–1141.

    CAS  PubMed  Google Scholar 

  8. Rossi A, Delbue S, Mazziotti R, Valli M, Borghi E, Mancuso R et al. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 2007; 79: 408–412.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Vermont, Burlington, VT, USA

    R E Kast

  2. Division of Hematology, Azienda Ospedaliera Santa Chiara, University of Pisa, Pisa, Italy

    D Focosi & M Petrini

  3. Department of Physical Medicine, UMDNJ, Newark, NJ, USA

    E L Altschuler

Authors
  1. R E Kast
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Focosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Petrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E L Altschuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R E Kast.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kast, R., Focosi, D., Petrini, M. et al. Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant 39, 811–812 (2007). https://doi.org/10.1038/sj.bmt.1705682

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705682

  • Springer Nature Limited

This article is cited by

Search

Navigation